The clinical information you need, at your fingertips.

Adults need 560 to 610 minutes of moderate-to-vigorous activity per week to cut cardiovascular risk by more than 30%, far above the 150-minute floor most guidelines set. . .

Lilly’s investigational triple agonist produced nearly 30% mean weight loss over two years, with almost half of participants achieving weight reductions historically associated with surgery. . .

Two studies suggest image-based AI tools may better identify women who'd benefit from prevention, predicting long-term risk more accurately than standard clinical models and performing consistently across racial and ethnic groups. . .

Updated ACC/AHA guidance emphasizes earlier intervention, new risk tools, and expanded use of nonstatins to reach lower LDL targets. . .

A century-old dye and antioxidant boosted hair follicle stem cell proliferation, accelerated wound closure, and protected cells from the metabolic stress caused by GLP-1 receptor agonists, in cultured human cells. . .

Beqalzi (sonrotoclax) represents a new targeted option for relapsed or refractory mantle cell lymphoma after prior Bruton tyrosine kinase (BTK) inhibitor therapy. . .

A ten-year Massachusetts analysis points to a steady shift in where children's mental health needs are showing up, with anxiety driving the steepest rise. . .

Fasenra (benralizumab) becomes a new targeted option for hypereosinophilic syndrome, where disease flares are often managed with chronic corticosteroids. . .

Online narratives are reshaping patient expectations—and complicating evidence-based care. . .